New laboratory tests can detect minimally elevated levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients with undetectable ultrasensitive troponin ( Conclusion The undetectable ultrasensitive troponin T values in patients with chest pain and no signs of ischemia on the electrocardiogram has an accuracy close to 100%…
Melody
The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy of Fallot with pulmonary atresia, truncus arteriosus, transposition of great arteries with VSD, pulmonary stenosis, etc.The Melody trans catheter pulmonary valve is composed of three leaflets of bovine jugular vein mounted…
ALECARDIO Trial: Aleglitazar associated with severe adverse events in diabetic patients with acute coronary syndrome
This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile of Aleglitazar, compared with placebo in patients with type 2 diabetes experiencing an acute coronary syndrome. A total of 7226 patients were randomized at 12 weeks post-acute coronary event to receive Aleglitazar 150 ug or placebo. The study…
GAUSS -2: Evolocumab effective in reducing LDL cholesterol in patients intolerant to statins
Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption of about 10-20%.The Evolocumab is a fully human monoclonal antibody that inhibits a protein converting subtilisin/ kexin type 9 (PCSK 9); this is a protein that reduces the liver’s ability to remove LDL cholesterol from theblood.This is a…
Global Registry SYMPLICITY demonstrated the safety of renal denervation system
The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal denervation safety and effectiveness in a real-world population with refractory hypertension. It plans to prospectively include a minimum of 5000 patients with refractory hypertension in 200 centers worldwide.In the 6-month analysis of the first 1000 patients included so…
MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.
The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention with cardiac resynchronization therapy plus defibrillator in patients with electrical block pattern of complete left bundle branch was associated with a significant reduction of events in a mean follow-up of 2.4 years compared with the defibrillation therapy only.In…
LAPLACE 2: Evolocumab effective in reducing LDL associated with statins
There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that inhibits protein converting subtilisin / kexin type 9 (PCSK9) showed lowering LDL cholesterol in phase 2 studies. The objective of this Phase 3 study was to evaluate the safety and efficacy…
CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.
Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the treatment of multiple recurrences. 240patients were randomized to colchicine plus conventional anti-inflammatory scheme (aspirin, ibuprofen or indomethacin). The primary endpoint was the rate of recurrence of pericarditis in 18 months. The…
STABILITY Trial: Daraplabid no benefits in chronic coronary artery disease
Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing cardiovascular events in patients with chronic ischemic heart disease.Lp-PLA2 is an enzyme found in the blood andatherosclerotic plaques and high levels are associated with an increased risk of cardiovascular events.Direct inhibition of this enzyme with proinflammatory Daraplabid may…
CHOICE Trial: Same mortality, less aortic regurgitation and need for a second prosthetic for Edwards Sapien XT valve versus Medtronic CoreValve
So far, there had been no published randomized studies comparing balloon-expandable Edwards’s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in…